Comparison
Citicoline vs Melatonin
Side-by-side of Citicoline and Melatonin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Melatonin
Melatonin as a sleep supplement: 0.3-1 mg matches physiological output, 3-10 mg is pharmacological. Shifts circadian phase, shortens sleep latency.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Melatonin
- •Shortens sleep onset latency by ~7 to 12 minutes at physiological 0.3 to 1 mg doses
- •Advances circadian phase when taken 30 to 60 minutes before target bedtime, useful for jet lag and shift work
- •Does not meaningfully increase total sleep time in healthy adults without circadian misalignment
- •Endogenous nighttime production is not suppressed by short-term exogenous supplementation
- •Higher doses (3 to 10 mg) raise plasma levels above physiological range and often increase morning grogginess
- •Effective for delayed sleep-wake phase disorder and reducing jet-lag severity in eastward travel
Side-by-side
| Attribute | Citicoline | Melatonin |
|---|---|---|
| Category | supplement | supplement |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | N-acetyl-5-methoxytryptamine |
| Half-life (hr) ↗ | 56 | 0.75 |
| Typical dose (mg) ↗ | 500 | 0.5 |
| Dosing frequency | 1 to 2 times daily | daily, 30 to 60 minutes before target sleep time |
| Routes | oral, intravenous | oral, sublingual |
| Onset (hr) | 1 | 0.5 |
| Peak (hr) | 2 | 1 |
| Molecular weight | 488.32 | 232.28 |
| Molecular formula | C14H26N4O11P2 | C13H16N2O2 |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Agonist at MT1 and MT2 receptors in the suprachiasmatic nucleus, signaling biological night and promoting sleep-onset gating plus circadian phase shifts. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | OTC in US; prescription in UK, EU, Japan |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement (US); Rx in most of the world | OTC supplement in US; Rx in UK, EU, Japan, Australia |
| Pregnancy | Insufficient data for routine use | Insufficient data; not routinely recommended |
| CAS | 987-78-0 | 73-31-4 |
| PubChem CID | 13804 | 896 |
| Wikidata | Q411470 | Q179243 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Melatonin
Common side effects
- vivid dreams
- morning grogginess (higher doses)
- headache
- dizziness
Contraindications
- autoimmune disease (theoretical)
- concurrent anticoagulant therapy without monitoring
Interactions
- fluvoxamine: CYP1A2 inhibition raises melatonin levels substantially(major)
- warfarin: possible increased bleeding risk(moderate)
- benzodiazepines and alcohol: additive sedation(moderate)
- antihypertensives: may alter blood pressure response(minor)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Melatonin is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is sleep onset or sleep quality, pick Melatonin.
- → If your priority is circadian regulation, pick Melatonin.
Edge case: Half-lives differ materially (Citicoline ~56 hr vs Melatonin ~0.75 hr). Citicoline reaches steady state faster; Melatonin is easier to dial in if tolerability is uncertain.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for Melatonin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and Melatonin?
Citicoline and Melatonin differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or Melatonin?
Citicoline half-life is 56 hours; Melatonin half-life is 0.75 hours.
Can you stack Citicoline with Melatonin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper